Kura Oncology, Inc.
Price Action
Technical Summary
CONSOLIDATINGKura Oncology, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 76), indicating performance broadly in line with the market. Earnings contraction of 26% provides fundamental context to the price action. However, price is extended 23% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.09 | +18.79% | ABOVE |
| 50 SMA | $9.71 | +23.43% | ABOVE |
| 100 SMA | $9.19 | +30.53% | ABOVE |
| 150 SMA | $9.36 | +28.09% | ABOVE |
| 200 SMA | $9.51 | +26.08% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KURA in an uptrend right now?
KURA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is KURA overbought or oversold?
KURA's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is KURA outperforming the market?
KURA has a Relative Strength (RS) Rating of 76 out of 99. KURA is performing about average compared to the market.
Where is KURA in its 52-week range?
KURA is trading at $11.99, which is 96% of its 52-week high ($12.49) and 93% above its 52-week low ($5.45).
How volatile is KURA?
KURA has a Beta of 1.47 and 52-week volatility of 60%. It's more volatile than the S&P 500 - expect bigger swings.